Royalty Pharma plc Files 8-K on Security Holder Votes

Ticker: RPRX · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1802768

Royalty Pharma PLC 8-K Filing Summary
FieldDetail
CompanyRoyalty Pharma PLC (RPRX)
Form Type8-K
Filed DateJun 6, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: RPRX

TL;DR

Royalty Pharma held a shareholder vote, details to follow.

AI Summary

Royalty Pharma plc filed an 8-K on June 6, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about the specific proposals voted on or the outcomes.

Why It Matters

This filing indicates that Royalty Pharma plc held a vote of its security holders, which is a standard corporate governance procedure. The specific details of the vote are not provided in this initial report.

Risk Assessment

Risk Level: low — This is a routine corporate filing regarding a shareholder vote, with no immediate financial or operational impact disclosed.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Royalty Pharma plc's security holders?

The filing does not specify the exact proposals or matters that were submitted for a vote.

When did the vote by security holders take place?

The filing indicates the report is as of June 6, 2024, suggesting the vote occurred on or around this date.

What were the results of the vote?

The filing does not disclose the outcome or results of the security holder vote.

Is this filing related to any new business or acquisition for Royalty Pharma plc?

This filing is specifically for the submission of matters to a vote of security holders and does not mention new business or acquisitions.

Where is Royalty Pharma plc's principal executive office located?

Royalty Pharma plc's principal executive offices are located at 110 East 59th Street, New York, New York 10022.

Filing Stats: 939 words · 4 min read · ~3 pages · Grade level 9.8 · Accepted 2024-06-06 17:06:32

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 6, 2024 ROYALTY PHARMA PLC By: /s/ George Lloyd George Lloyd Executive Vice President, Investments & Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing